Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism.

  title={Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism.},
  author={Anders Hviid and Mads Melbye and Bj{\"o}rn Pasternak},
  journal={The New England journal of medicine},
  volume={369 25},
BACKGROUND Studies have raised concern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and an increased risk of autism spectrum disorders in the offspring. METHODS We conducted a cohort study of all singleton live births in Denmark from 1996 through 2005 (626,875 births), with follow-up through 2009. Using Danish population registries, we linked information on maternal use of SSRIs before and during pregnancy, autism spectrum disorders… 

Tables from this paper

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study
The mildly increased risk of ASD in the offspring associated with paternal SSRIs use before conception may be attributable to paternal underlying psychiatric indications related to SSRI use or other unmeasured confounding factors.
In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder
Evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD is found and these results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study.
Association Between Maternal Use of SSRI Medications and Autism in Their Children.
  • B. King
  • Medicine, Psychology
  • 2017
Examination of pregnancies from 1998 to 2009 in the Quebec Pregnancy/Children Cohort database that resulted in children with autism spectrum disorder (ASD) as the primary outcome concluded that second- or third-trimester exposure to SSRIs was associated with increased risk for ASD.
Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.
Exposure to SSRIs during pregnancy was associated with an increased risk of speech/language disorders in offspring up to early adolescence, and this finding may have implications for understanding associations betweenSSRIs and child development.
Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children
In children born to mothers receiving public drug coverage in Ontario, Canada, in utero serotonergic antidepressant exposure compared with no exposure was not associated with autism spectrum disorder in the child, and the previously observed association may be explained by other factors.
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence
It is recommended that pregnant women exposed to any SSRI in early pregnancy be offered options for prenatal diagnosis through ultrasound examinations and fetal echocardiography to detect the presence of birth defects.
Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children.
Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, even after considering maternal depression.
Prenatal Antidepressant Use and Risk of Autism Spectrum Disorders in Children.
To the Editor The register-based cohort study by Boukhris et al1 investigating the association between prenatal antidepressant use and risk of autism spectrum disorders (ASD) in the offspring was


Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study
In utero exposure to both SSRIs and non-selective monoamine reuptake inhibitors (tricyclic antidepressants) was associated with an increased risk of autism spectrum disorders, particularly without intellectual disability.
Investigating Outcomes Following the Use of Selective Serotonin Reuptake Inhibitors for Treating Depression in Pregnancy
Evidence of associations between prenatal SSRI exposure and adverse pregnancy outcomes are conflicting, there is an urgent need to evaluate how the particular SSRI used, the dose, timing and duration of use, genetics, concomitant medication use, maternal characteristics and underlying maternal illness all interact to alter pregnancy outcomes.
Antidepressant use during pregnancy and childhood autism spectrum disorders.
Although the number of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low, results suggest that exposure, especially during the first trimester, may modestly increase the risk of ASD.
Use of antidepressant medications during pregnancy: a multisite study.
Fetal serotonin signaling: setting pathways for early childhood development and behavior.
  • T. Oberlander
  • Psychology, Biology
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • 2012
Depression and anxiety during pregnancy: A risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature
  • J. Alder, Nadine S Fink, J. Bitzer, I. Hösli, W. Holzgreve
  • Medicine, Psychology
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2007
Elevated levels of depression and anxiety symptoms during pregnancy contribute independently of other biomedical risk factors to adverse obstetric, fetal and neonatal outcome, however, conclusions for women with mood or anxiety disorders are limited.
Epidemiology of Pervasive Developmental Disorders
There is evidence that the broadening of the concept, the expansion of diagnostic criteria, the development of services, and improved awareness of the condition have played a major role in explaining this increase, although it cannot be ruled out that other factors might have also contributed to that trend.
Validity of Childhood Autism in the Danish Psychiatric Central Register: Findings from a Cohort Sample Born 1990–1999
In 499 children diagnosed with childhood autism in the DPCR, the diagnosis could be confirmed in 469 children (94%) and 30 non-confirmed cases were classified by the reviewers as non-autistic cases and the remaining 25 cases were either classified with another ASD diagnosis or the specific diagnosis was not possible to determine.